These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1700 related items for PubMed ID: 18263627

  • 1. 11C PiB and structural MRI provide complementary information in imaging of Alzheimer's disease and amnestic mild cognitive impairment.
    Jack CR, Lowe VJ, Senjem ML, Weigand SD, Kemp BJ, Shiung MM, Knopman DS, Boeve BF, Klunk WE, Mathis CA, Petersen RC.
    Brain; 2008 Mar; 131(Pt 3):665-80. PubMed ID: 18263627
    [Abstract] [Full Text] [Related]

  • 2. Comparison of MRI based and PET template based approaches in the quantitative analysis of amyloid imaging with PIB-PET.
    Edison P, Carter SF, Rinne JO, Gelosa G, Herholz K, Nordberg A, Brooks DJ, Hinz R.
    Neuroimage; 2013 Apr 15; 70():423-33. PubMed ID: 23261639
    [Abstract] [Full Text] [Related]

  • 3. Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: implications for sequence of pathological events in Alzheimer's disease.
    Jack CR, Lowe VJ, Weigand SD, Wiste HJ, Senjem ML, Knopman DS, Shiung MM, Gunter JL, Boeve BF, Kemp BJ, Weiner M, Petersen RC, Alzheimer's Disease Neuroimaging Initiative.
    Brain; 2009 May 15; 132(Pt 5):1355-65. PubMed ID: 19339253
    [Abstract] [Full Text] [Related]

  • 4. Characterizing regional correlation, laterality and symmetry of amyloid deposition in mild cognitive impairment and Alzheimer's disease with Pittsburgh Compound B.
    Raji CA, Becker JT, Tsopelas ND, Price JC, Mathis CA, Saxton JA, Lopresti BJ, Hoge JA, Ziolko SK, DeKosky ST, Klunk WE.
    J Neurosci Methods; 2008 Jul 30; 172(2):277-82. PubMed ID: 18582948
    [Abstract] [Full Text] [Related]

  • 5. Tau PET patterns mirror clinical and neuroanatomical variability in Alzheimer's disease.
    Ossenkoppele R, Schonhaut DR, Schöll M, Lockhart SN, Ayakta N, Baker SL, O'Neil JP, Janabi M, Lazaris A, Cantwell A, Vogel J, Santos M, Miller ZA, Bettcher BM, Vossel KA, Kramer JH, Gorno-Tempini ML, Miller BL, Jagust WJ, Rabinovici GD.
    Brain; 2016 May 30; 139(Pt 5):1551-67. PubMed ID: 26962052
    [Abstract] [Full Text] [Related]

  • 6. Conversion of amyloid positive and negative MCI to AD over 3 years: an 11C-PIB PET study.
    Okello A, Koivunen J, Edison P, Archer HA, Turkheimer FE, Någren K, Bullock R, Walker Z, Kennedy A, Fox NC, Rossor MN, Rinne JO, Brooks DJ.
    Neurology; 2009 Sep 08; 73(10):754-60. PubMed ID: 19587325
    [Abstract] [Full Text] [Related]

  • 7. Tau pathology and neurodegeneration contribute to cognitive impairment in Alzheimer's disease.
    Bejanin A, Schonhaut DR, La Joie R, Kramer JH, Baker SL, Sosa N, Ayakta N, Cantwell A, Janabi M, Lauriola M, O'Neil JP, Gorno-Tempini ML, Miller ZA, Rosen HJ, Miller BL, Jagust WJ, Rabinovici GD.
    Brain; 2017 Dec 01; 140(12):3286-3300. PubMed ID: 29053874
    [Abstract] [Full Text] [Related]

  • 8. Diagnostic role of 11C-Pittsburgh compound B retention patterns and glucose metabolism by fluorine-18-fluorodeoxyglucose PET/CT in amnestic and nonamnestic mild cognitive impairment patients.
    Jiménez-Bonilla JF, Banzo I, De Arcocha-Torres M, Quirce R, Martínez-Rodríguez I, Lavado-Pérez C, Bravo-Ferrer Z, Rodríguez-Rodríguez E, Sánchez-Juan P, Carril JM.
    Nucl Med Commun; 2016 Nov 01; 37(11):1189-96. PubMed ID: 27341411
    [Abstract] [Full Text] [Related]

  • 9. Comparison study of amyloid PET and voxel-based morphometry analysis in mild cognitive impairment and Alzheimer's disease.
    Waragai M, Okamura N, Furukawa K, Tashiro M, Furumoto S, Funaki Y, Kato M, Iwata R, Yanai K, Kudo Y, Arai H.
    J Neurol Sci; 2009 Oct 15; 285(1-2):100-8. PubMed ID: 19552926
    [Abstract] [Full Text] [Related]

  • 10. Independent contribution of temporal beta-amyloid deposition to memory decline in the pre-dementia phase of Alzheimer's disease.
    Chételat G, Villemagne VL, Pike KE, Ellis KA, Bourgeat P, Jones G, O'Keefe GJ, Salvado O, Szoeke C, Martins RN, Ames D, Masters CL, Rowe CC, Australian Imaging Biomarkers and Lifestyle Study of ageing (AIBL) Research Group.
    Brain; 2011 Mar 15; 134(Pt 3):798-807. PubMed ID: 21310725
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. The effect of amyloid β on cognitive decline is modulated by neural integrity in cognitively normal elderly.
    Wirth M, Oh H, Mormino EC, Markley C, Landau SM, Jagust WJ.
    Alzheimers Dement; 2013 Nov 15; 9(6):687-698.e1. PubMed ID: 23474040
    [Abstract] [Full Text] [Related]

  • 17. Comparison of [18F]Flutemetamol and [11C]Pittsburgh Compound-B in cognitively normal young, cognitively normal elderly, and Alzheimer's disease dementia individuals.
    Lowe VJ, Lundt E, Knopman D, Senjem ML, Gunter JL, Schwarz CG, Kemp BJ, Jack CR, Petersen RC.
    Neuroimage Clin; 2017 Nov 15; 16():295-302. PubMed ID: 28856092
    [Abstract] [Full Text] [Related]

  • 18. Clinical impact of 11C-Pittsburgh compound-B positron emission tomography in addition to magnetic resonance imaging and single-photon emission computed tomography on diagnosis of mild cognitive impairment to Alzheimer's disease.
    Kitajima K, Abe K, Takeda M, Yoshikawa H, Ohigashi M, Osugi K, Koyama H, Yamakado K.
    Medicine (Baltimore); 2021 Jan 22; 100(3):e23969. PubMed ID: 33545981
    [Abstract] [Full Text] [Related]

  • 19. Beta-amyloid burden in the temporal neocortex is related to hippocampal atrophy in elderly subjects without dementia.
    Bourgeat P, Chételat G, Villemagne VL, Fripp J, Raniga P, Pike K, Acosta O, Szoeke C, Ourselin S, Ames D, Ellis KA, Martins RN, Masters CL, Rowe CC, Salvado O, AIBL Research Group.
    Neurology; 2010 Jan 12; 74(2):121-7. PubMed ID: 20065247
    [Abstract] [Full Text] [Related]

  • 20. Non-invasive assessment of Alzheimer's disease neurofibrillary pathology using 18F-THK5105 PET.
    Okamura N, Furumoto S, Fodero-Tavoletti MT, Mulligan RS, Harada R, Yates P, Pejoska S, Kudo Y, Masters CL, Yanai K, Rowe CC, Villemagne VL.
    Brain; 2014 Jun 12; 137(Pt 6):1762-71. PubMed ID: 24681664
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 85.